Latest Conference Coverage


Barry Byrne, MD, PhD

SGT-001 Shows Improvements in Key DMD Measures, Microdystrophin Expression

March 31st 2021

Preliminary results from the IGNITE-DMD trial also showed a decreased in creatine kinase levels and improvements on NSAA and PODCI.


Expanding Research on MS Diagnosis Disclosure and Long-Term Impacts: Anne Kever, PhD

Expanding Research on MS Diagnosis Disclosure and Long-Term Impacts: Anne Kever, PhD

March 31st 2021

The postdoctoral researcher at Columbia University discussed the long-term plans to gain a better understanding of MS diagnosis disclosure and how it can impact other qualities of life.


NeuroVoices: Ralph Sacco, MD, MS, on Florida Stroke Registry, Advancing Stroke Knowledge

NeuroVoices: Ralph Sacco, MD, MS, on Florida Stroke Registry, Advancing Stroke Knowledge

March 31st 2021

The chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine discussed the abundance of research from the Florida Stroke Registry presented at ISC 2021.


Spencer Hutto, MD

CNS Demyelination and Autoimmune Neurology: Spencer Hutto, MD

March 30th 2021

The fellow of autoimmune neurology at Massachusetts General Hospital also discussed concerns of associations between multiple sclerosis and COVID-19.


Kimberley Allen-Philbey

Off-Label, Personalized Cladribine Dosing: Kimberly Allen-Philbey

March 29th 2021

The PhD candidate at the Barts MS Center in London discussed her study presented at ACTRIMS Forum 2021 that evaluated CPD in patients with relapsing MS.


Tahseen Mozaffar, MD, FAAN

AT-GAA More Efficacious than Alglucosidase Alfa in Late-Onset Pompe Disease

March 27th 2021

Researchers observed improvements in motor and respiratory function and biomarkers in the investigational treatment group.


Understanding the Complex Diagnosis of Genetic Leukodystrophies: Alise Carlson, MD

Understanding the Complex Diagnosis of Genetic Leukodystrophies: Alise Carlson, MD

March 27th 2021

Alise Carlson, MD, a resident at Cleveland Clinic, detailed the reasons for her study evaluating genetic leukodystrophies and their differences to multiple sclerosis at diagnosis.


Viz LVO Software Accurately Detects LVOs in Real-World Setting

Viz LVO Software Accurately Detects LVOs in Real-World Setting

March 27th 2021

The triage software yielded a sensitivity and specificity of 59.7% and 91.5%, respectively, for all scans in a study including more than 1000.


Florida Stroke Registry Serves as Trough of Valuable Research: Ralph Sacco, MD, MS, FAAN, FAHA

Florida Stroke Registry Serves as Trough of Valuable Research: Ralph Sacco, MD, MS, FAAN, FAHA

March 26th 2021

The chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine outlined the Florida Stroke Registry and its capabilities.


Tenecteplase Demonstrates Noninferiority to Alteplase in Acute Ischemic Stroke

Tenecteplase Demonstrates Noninferiority to Alteplase in Acute Ischemic Stroke

March 25th 2021

P values showed evidence of statistical significance at the conventional P <.05 threshold for all assessed non-inferiority margins.


Daniel Reich, MD, PhD

Understanding Chronic Inflammation in MS: Daniel Reich, MD, PhD

March 25th 2021

The senior investigator at the National Institutes of Neurological Disorders and Stroke outlined studies on anakinra and tolebrutinib as part of a new phase 2a clinical trial paradigm.


Wearable Gait Technology Shows Promise in SMA and DMD

Wearable Gait Technology Shows Promise in SMA and DMD

March 25th 2021

There was very good to excellent level of agreement between the instrumented insoles and the gold-standard reference system.


Jemima Akinsanya, DO

Studies of Anakinra and Tolebrutinib in MS Paramagnetic Rim Lesions: Jemima Akinsanya, DO

March 24th 2021

The Neuroimmunology Clinical Fellow at the National Institutes of Health discussed the evaluations of 2 therapies in multiple sclerosis that she is partaking in.


Steps Needed to Improve MS Diagnosis Disclosure Rates: Anne Kever, PhD

Steps Needed to Improve MS Diagnosis Disclosure Rates: Anne Kever, PhD

March 24th 2021

The postdoctoral researcher at Columbia University discussed ways clinicians and patients with multiple sclerosis can take to ease the transition of disclosing their diagnosis.


Tudor Jovin, MD

Endovascular Thrombectomy Benefits Observed 6 to 24 Hours Since Last Known Well

March 24th 2021

The AURORA collaboration studied pooled study data from 6 randomized studies of ET in ischemic stroke.


Susan Apkon, MD

Switch to Deflazacort Improves Disease Progression in Patients With Dystrophinopathies

March 23rd 2021

Researchers conducted a real-world study of prednisone to deflazacort switch in patients with Duchenne muscular dystrophy and Becker muscular dystrophy.


Yujie Wang, MD

Rare Reactions With Natalizumab Infusion: Yujie Wang, MD

March 23rd 2021

The neurologist from the University of Washington Medical Center discussed the findings of her recent study presented at ACTRIMS Forum 2021.


Despite Improvements, Racial Disparities in EVT Care Still Exist

Despite Improvements, Racial Disparities in EVT Care Still Exist

March 23rd 2021

Black patients were 16% less likely and Asian patients were 30% less likely to be able to function independently compared to non-Hispanic white patients following endovascular treatment.


Enzyme Replacement Therapy Shows Early Improvement in Pompe Disease

Enzyme Replacement Therapy Shows Early Improvement in Pompe Disease

March 23rd 2021

Assessment of forced vital capacity with treatment of enzyme replacement therapy generally showed some initial stability followed by slow progressive decline.


Eculizumab Demonstrates Safety, No Increased Infection Rates in NMOSD or Myasthenia Gravis

Eculizumab Demonstrates Safety, No Increased Infection Rates in NMOSD or Myasthenia Gravis

March 22nd 2021

The findings were consistent with the established safety profile for eculizumab in other non-neurologic indications, according to study authors.


The COVID Focus and the Top Talks at ACTRIMS 2021: Jeffrey Cohen, MD

The COVID Focus and the Top Talks at ACTRIMS 2021: Jeffrey Cohen, MD

March 22nd 2021

The president of the Americas Committee for Treatment and Research in MS shared his perspective on the impact of COVID and the top talks at the ACTRIMS Forum 2021.


Stephanie Blandford, MSc, PhD candidate

Challenges of Targeting Cytokines in MS: Stephanie Blandford, MSc

March 21st 2021

The PhD candidate at the neuroimmunology laboratory at Memorial University of Newfoundland discussed the potential of interleukin-1 receptor antagonist as a biomarker in MS disability as well as a therapeutic target.


ACTRIMS Forum 2021: Top Expert Interviews

ACTRIMS Forum 2021: Top Expert Interviews

March 21st 2021

NeurologyLive’s coverage of ACTRIMS Forum 2021 featured a number of insightful conversations with leading experts in multiple sclerosis care.


Efficacy and Tolerability on Display by SRP-9003 Over 2 Years in LGMD2E

Efficacy and Tolerability on Display by SRP-9003 Over 2 Years in LGMD2E

March 20th 2021

Over a 2-year period, SRP-9003 elicited sustained protein expression in muscle tissue and stabilized North Star Assessment for Dysferlinopathies scores.


American Heart Association Releases Results on COVID-19 and Stroke Characteristics, Prevalence

American Heart Association Releases Results on COVID-19 and Stroke Characteristics, Prevalence

March 19th 2021

Black patients accounted for 27% of the patients in the COVID-19 CVD Registry but accounted for 31% of the ischemic stroke cases.


Manuel Requena, MD, PhD

Direct Transfer to Angio Suite Reduces Likelihood of Severe Disability Post Stroke

March 19th 2021

Researchers also found that compared to direct to CT patients, DTAS patients has lower onset-to-reperfusion and door-to-groin times.

© 2025 MJH Life Sciences

All rights reserved.